<DOC> 
<DOCNO>1040115_business_story_2788443.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Thursday, January 15, 2004 				 Glenmark in deal with KV Pharma
 OUR CORRESPONDENT 																								Mumbai, Jan. 14: Glenmark Pharmaceuticals wholly-owned US subsidiary has entered into a product development and marketing licence agreement for eight generic products valued at $80 million with the US-based K V Pharmaceutical Company.																								Glenmark said the licensed products include paragraph III and paragraph IV abbreviated new drug application filing opportunities.																								The agreement provides for development and licensing of additional generic abbreviated new drugs application products as well as for certain branded speciality products, Glenmark added. 																								A successful para IV filing would give the generic drug makers exclusive marketing rights for six months.																								Though specific terms for the agreement with K V Pharmaceutical were not disclosed, Glenmark said it would include an initial cash payment and milestone and royalty payments from K V Pharmaceutical in exchange of the marketing rights to the Glenmark products. 
</TEXT> 
</DOC>